-
Je něco špatně v tomto záznamu ?
The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry
O. Chrapek, J. Jarkovsky, J. Studnicka, M. Sin, P. Kolar, B. Jirkova, L. Dusek, S. Pitrova, J. Rehak
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
- MeSH
- incidence MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- lidé MeSH
- makulární degenerace diagnóza farmakoterapie epidemiologie MeSH
- optická koherentní tomografie MeSH
- ranibizumab terapeutické užití MeSH
- registrace * MeSH
- retrospektivní studie MeSH
- senioři MeSH
- vaskulární endoteliální růstový faktor A antagonisté a inhibitory MeSH
- zraková ostrost MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
AIMS: TheAIM of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. METHODS: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. RESULTS: After 12 months of treatment, a loss of < 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of ≥ 15 letters was found in 9.7% of eyes on ranibizumab. The results for our patients treated in clinical practice with ranibizumab were poorer than those in the SUSTAIN (Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) study. A rationale for this was sought in a sub-analysis. CONCLUSIONS: Sub-analysis demonstrated that treatment naive CNV (choroidal neovascularization), occult CNV and lower height of the macular oedema at the outset of the disease may be positive prognostic factors for final visual acuity in anti-VEGF (vascular endothelial growth factor) treated patients.
Department of Ophthalmology Faculty of Medicine Masaryk University Brno and University Hospital Brno
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17004283
- 003
- CZ-PrNML
- 005
- 20170307122903.0
- 007
- ta
- 008
- 170127s2015 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2015.017 $2 doi
- 024 7_
- $a 10.5507/bp.2015.017 $2 doi
- 035 __
- $a (PubMed)25916281
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Chrapek, Oldřich, $u Department of Ophthalmology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1969- $7 xx0037582
- 245 14
- $a The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry / $c O. Chrapek, J. Jarkovsky, J. Studnicka, M. Sin, P. Kolar, B. Jirkova, L. Dusek, S. Pitrova, J. Rehak
- 520 9_
- $a AIMS: TheAIM of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. METHODS: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. RESULTS: After 12 months of treatment, a loss of < 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of ≥ 15 letters was found in 9.7% of eyes on ranibizumab. The results for our patients treated in clinical practice with ranibizumab were poorer than those in the SUSTAIN (Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) study. A rationale for this was sought in a sub-analysis. CONCLUSIONS: Sub-analysis demonstrated that treatment naive CNV (choroidal neovascularization), occult CNV and lower height of the macular oedema at the outset of the disease may be positive prognostic factors for final visual acuity in anti-VEGF (vascular endothelial growth factor) treated patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a inhibitory angiogeneze $x terapeutické užití $7 D020533
- 650 _2
- $a Česká republika $x epidemiologie $7 D018153
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a makulární degenerace $x diagnóza $x farmakoterapie $x epidemiologie $7 D008268
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ranibizumab $x terapeutické užití $7 D000069579
- 650 12
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a optická koherentní tomografie $7 D041623
- 650 _2
- $a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
- 650 _2
- $a zraková ostrost $7 D014792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jarkovský, Jiří $u Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University, Brno $7 stk2008461294
- 700 1_
- $a Studnička, Jan $u Department of Ophthalmology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital in Hradec Kralove $7 jx20090420023
- 700 1_
- $a Šín, Martin $u Department of Ophthalmology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0095569
- 700 1_
- $a Kolář, Petr, $u Department of Ophthalmology, Faculty of Medicine, Masaryk University Brno and University Hospital Brno $d 1970- $7 xx0037722
- 700 1_
- $a Chrapková, Barbora $u Department of Ophthalmology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0238672
- 700 1_
- $a Dušek, Ladislav, $u Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University, Brno $d 1967- $7 mzk2003181727
- 700 1_
- $a Pitrová, Šárka, $u Private Eye Clinic, V Hurkach 1296/10, Prague $d 1947- $7 mzk2006348964
- 700 1_
- $a Řehák, Jiří, $u Department of Ophthalmology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1958- $7 nlk19990074207
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 3 (2015), s. 407-412
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170127 $b ABA008
- 991 __
- $a 20170306132950 $b ABA008
- 999 __
- $a ok $b bmc $g 1192260 $s 964898
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 159 $c 3 $d 407-412 $e 20150424 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170127
